Tous Actualités
Suivre
Abonner AGENNIX AG

AGENNIX AG

EANS-News: AGENNIX AG
Agennix AG Schedules Conference Call on November 18, 2010 to Discuss Third Quarter 2010 Financial Results

Heidelberg (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
9-month report/Conference Call
Planegg/Munich (Germany), Princeton, NJ and
Houston, TX, October 28, 2010 - Agennix AG (Frankfurt Stock Exchange:
AGX) today announced that the Company will hold a conference call to 
discuss financial results for the third quarter and first nine months
of 2010 and to provide a business update. The results will be 
published on Thursday, November 18, 2010 in advance of the conference
call. Please note that this date is a change from the previously 
announced date of November 4, 2010.
The conference call, which will be conducted in English, will be held
on Thursday, November 18, 2010 at 9 AM ET/3 PM CET.
A live webcast will be available on the Agennix Web site at 
www.agennix.com. A replay will be available via the Web site 
following the live event.
Dial-in numbers for the call are as follows:
Participants from Europe:       0049 (0)69 71044 5598
                                0044 (0)20 3003 2666
Participants from the U.S.:     1 212 999 6659
Please dial in 10 minutes before the beginning of the call.
About Agennix Agennix AG is a publicly listed biopharmaceutical 
company that is focused on the development of novel therapies that 
have the potential to substantially improve the length and quality of
life of critically ill patients in areas of major unmet medical need.
The Company´s most advanced program is talactoferrin, an oral therapy
that has demonstrated activity in randomized, double-blind, 
placebo-controlled Phase II studies in non-small cell lung cancer, as
well as in severe sepsis. Talactoferrin is currently in Phase III 
clinical trials in non-small cell lung cancer, and Agennix plans to 
develop this program further for the treatment of severe sepsis. 
Other clinical development programs include RGB-286638, a 
multi-targeted kinase inhibitor in Phase I testing; the oral 
platinum-based compound satraplatin; and a topical gel form of 
talactoferrin for diabetic foot ulcers. Agennix´s registered seat is 
in Heidelberg, Germany. The Company has three sites of operation: 
Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas. 
For additional information, please visit the Agennix Web site at 
www.agennix.com.
This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to 
risks and uncertainties, many of which are beyond our control, that 
could cause future results, performance or achievements to differ 
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could 
differ materially depending on a number of factors, and we caution 
investors not to place undue reliance on the forward-looking 
statements contained in this press release. Forward-looking 
statements speak only as of the date on which they are made and 
Agennix undertakes no obligation to update these forward-looking 
statements, even if new information becomes available in the future.
Agennix™ is a trademark of the Agennix group.
end of announcement                               euro adhoc

Further inquiry note:

Agennix AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com

Additional media contacts for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade

Plus de actualités: AGENNIX AG
Plus de actualités: AGENNIX AG